Prothena Corp PLC (NAS:PRTA)
$ 20.81 0.6 (2.97%) Market Cap: 1.12 Bil Enterprise Value: 584.98 Mil PE Ratio: 0 PB Ratio: 2.23 GF Score: 68/100

Prothena Corporation PLC to Discuss Results of the Phase 3 VITAL Amyloidosis Study - Conference Call Transcript

Apr 18, 2019 / 08:30PM GMT
Release Date Price: $10.7 (-0.56%)
Operator

Good day, ladies and gentlemen, and welcome to the Phase III VITAL Study Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Ms. Ellen Rose. Ma'am, you may begin.

Ellen Rose
Prothena Corporation plc - Head of Communications

Thank you, Valerie. Good afternoon, everyone, and welcome to Prothena's investor conference call to review the final results from the Phase III VITAL Amyloidosis Study. Please review the press release we issued earlier today, which is available at our website at prothena.com and is also attached to a Form 8-K that was filed today with the SEC. The slides for this presentation are available in the Investors section of our website and also include Appendix slides with additional detail.

Speaking on today's call, we have Dr. Gene Kinney, our President and Chief Executive Officer, who will provide an overview of the results; Dr. Wagner Zago, our Chief Scientific Officer, will discuss the mechanisms of action and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot